Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

---

Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 17, 2025

In situ vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy, offering targeted approach that uses the tumor microenvironment (TME) to stimulate an immune response directly at site. This method minimizes systemic exposure while maintaining therapeutic efficacy and enhancing safety. Recent advances nanotechnology have enabled new approaches ISV by utilizing nanomaterials with unique properties, including enhanced permeability, retention, controlled drug release. employing can induce immunogenic cell death reverse immunosuppressive hypoxic TME, thereby converting "cold" into "hot" facilitating more robust response. review examines mechanisms through which nanomaterials-based enhances anti-tumor immunity, summarizes clinical applications of these strategies, evaluates its capacity serve neoadjuvant therapy for eliminating micrometastases early-stage patients. Challenges associated translation ISV, nanomaterial metabolism, optimization treatment protocols, integration other therapies such radiotherapy, chemotherapy, photothermal therapy, are also discussed. Advances immunotherapy continue expand possible potentially leading improved outcomes across broad range types.

Language: Английский

---

An update on the clinical trial research of immunotherapy for glioblastoma

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Glioblastoma multiforme (GBM) is a common primary malignant brain tumor in adults, characterized by high rate of recurrence and mortality. The median overall survival less than 2 years with the current standard therapy. As immunotherapy has begun to show promising results solid tumors such as non-small cell lung cancer melanoma recent years, immnunotherapy for patients glioblastoma also full swing, which mainly consisted immune checkpoint inhibitors, vaccines, chimeric antigen receptor T-cell oncolytic viral However, application severely hampered cognitive impairment intracerebral lymphatic system, existence blood-brain barrier, highly immunosuppressive microenvironment GBM’s intrinsic features, including low mutation burden heterogeneity. This review systematically evaluates recently published clinical trial outcomes GBM immunotherapy, critically analyses both progress limitations these trials, thoroughly examines barriers effective highlights preclinical studies that may guide future therapeutic development.

Language: Английский

---

Assessing the prognostic role of panimmune inflammation in high-grade gliomas

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: 27(3), P. 1320 - 1328

Published: Aug. 14, 2024

Language: Английский

---

Exploring the prognostic value and potential therapeutic strategies of MS4A6A in glioblastoma: A comprehensive analysis of single‐cell and multi‐omics data

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(20)

Published: Oct. 1, 2024

Abstract Glioblastoma (GBM) is a highly aggressive and treatment‐resistant malignancy that poses significant challenge in modern medicine. Despite advances surgical resection, radiotherapy chemotherapy, complete eradication of GBM remains elusive due to its diffuse invasion into the brain parenchyma propensity for recurrence. The tumour microenvironment (TME), particularly macrophages, has emerged as critical player progression, metastasis. In immune glioma, MS4A6A exhibits unique expression characteristics macrophages. This study aimed investigate potential role MS4A6A, gene associated with aging neurodegenerative diseases, prognostic biomarker therapeutic target.

Language: Английский

---